C:\Program Files\Stnexp\Queries\09993647 (b).str





chain nodes :
7 8 9 10 17 18 19 20 21 22 26 27 28 29 30 31 32 33 34
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
1-29 2-27 3-22 4-28 5-7 6-30 7-8 8-9 8-10 9-13 11-34 12-33 14-31 15-32 16-17
17-18 18-19 19-20 19-21 21-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 8-10 9-13 16-17 17-18 18-19 19-20 19-21 21-26
exact bonds :
1-29 2-27 3-22 4-28 6-30 11-34 12-33 14-31 15-32
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

G1:H,CH3

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS
34:CLASS
Generic attributes :
18:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 18: Limited

C,C5
N,N1
O,O0
S,S0

=>
Uploading C:\Program Files\Stnexp\Queries\09993647.str



chain nodes :
7 8 9 10 17 19 20 21 22 23
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
5-7 7-8 8-9 8-10 9-13 17-19 19-20 20-21 20-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 8-10 9-13 17-19 19-20 20-21 20-22
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:Atom 19:Atom
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:Atom
Generic attributes :
19:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System : Monocyclic

Element Count :
Node 19: Limited
C,C5
N,N1
O,O0
S,S0

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\Stnexp\Queries\09993647 (a).str





chain nodes :
7 8 9 10 17 19 20 21 22 23 28
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
5-7 7-8 8-9 8-10 9-13 17-19 19-20 20-21 20-22 22-28
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 8-10 9-13 17-19 19-20 20-21 20-22 22-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
isolated ring systems :
containing 1 : 11 :

```
G1:H,CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:Atom  19:Atom
20:CLASS  21:CLASS  22:CLASS  23:CLASS  24:Atom  28:CLASS
Generic attributes :
19:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic

Element Count :
Node 19: Limited
    C,C5
    N,N1
    O,O0
    S,S0




L2      STRUCTURE UPLOADED

=> d l2
L2 HAS NO ANSWERS
L2              STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.


=> s l2 sss sam
SAMPLE SEARCH INITIATED 07:48:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      839 TO ITERATE

100.0% PROCESSED      839 ITERATIONS                              43 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        15043 TO    18517
PROJECTED ANSWERS:             467 TO     1253

L3           43 SEA SSS SAM L2

=> => ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end


=> screen 1840
```

L4 SCREEN CREATED

=> screen 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2047

L5 SCREEN CREATED

=>
Uploading C:\Program Files\Stnexp\Queries\09993647 (b).str





chain nodes :
7 8 9 10 17 18 19 20 21 22 26 27 28 29 30 31 32 33 34
ring nodes :
1 2 3 4 5 6 11 12 13 14 15 16
chain bonds :
1-29 2-27 3-22 4-28 5-7 6-30 7-8 8-9 8-10 9-13 11-34 12-33 14-31 15-32
16-17 17-18 18-19 19-20 19-21 21-26
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
exact/norm bonds :
5-7 7-8 8-9 8-10 9-13 16-17 17-18 18-19 19-20 19-21 21-26
exact bonds :

```
1-29  2-27  3-22  4-28  6-30  11-34  12-33  14-31  15-32
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  11-12  11-16  12-13  13-14  14-15  15-16
isolated ring systems :
containing 1 : 11 :


G1:H,CH3

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:Atom  12:Atom  13:Atom  14:Atom  15:Atom  16:Atom  17:CLASS  18:Atom  19:CLASS
20:CLASS  21:CLASS  22:CLASS  26:CLASS  27:CLASS  28:CLASS  29:CLASS  30:CLASS
31:CLASS  32:CLASS  33:CLASS  34:CLASS
Generic attributes :
18:
Saturation             : Unsaturated
Number of Carbon Atoms : less than 7
Number of Hetero Atoms : Exactly 1
Type of Ring System    : Monocyclic

Element Count :
Node 18: Limited
    C,C5
    N,N1
    O,O0
    S,S0




L6      STRUCTURE UPLOADED

=> que L6 AND L4 NOT L5

L7   QUE L6 AND L4 NOT L5

=> d l7
L7 HAS NO ANSWERS
L4              SCR 1840
L5              SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2047
L6              STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.
L7              QUE  L6 AND L4 NOT L5


=> s l7 sss sam
SAMPLE SEARCH INITIATED 07:53:29 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       29 TO ITERATE

100.0% PROCESSED       29 ITERATIONS                                4 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          257 TO      903
PROJECTED ANSWERS:               4 TO      200

L8            4 SEA SSS SAM L6 AND L4 NOT L5

=> => s l7 sss ful
FULL SEARCH INITIATED 07:54:19 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      509 TO ITERATE

100.0% PROCESSED      509 ITERATIONS                                78 ANSWERS
SEARCH TIME: 00.00.01

L9           78 SEA SSS FUL L6 AND L4 NOT L5

=> => s l9
L10       1515 L9

=> s bayer?
L11      10038 BAYER?

=> s l10 and l11
L12         11 L10 AND L11

=> d l12 1-11 bib,ab,hitstr
```

L12 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2010:317457 CAPLUS
DN 153:471241
TI Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (Sorafenib Hepatocarcinoma Assessment Randomized Protocol trial)
AU Detry, O.; Delwaide, J.; De Roover, A.; Meunier, P.; Van Daele, D.; Lamproye, A.; Honore, P.; Polus, M.
CS Service de Chirurgie Abdominale et Transplantation, CHU de Liege, Belg.
SO Revue Medicale de Liege (2009), 64(3), 168-170
CODEN: RMLIAC; ISSN: 0370-629X
PB Revue Medicale de Liege
DT Journal; General Review
LA French
AB A review. Curative management of early-stage hepatocarcinoma may include partial hepatic resection, liver transplantation or tumoral necrosis using radiofrequency ablation or alcoholisation. Until recently, no efficient therapeutic mean was available for advanced hepatocarcinoma. Sorafenib (Nexavar, Bayer) is a multikinase inhibitor that decreases tumoral proliferation and angiogenesis, and increases apoptosis in many cancer models. The results of a phase 3 randomized, multicentric, study, entitled SHARP, have now demonstrated that sorafenib increases survival in patients with advanced hepatocarcinoma developed in Child A cirrhosis. Mean survival gain was a little less than 3 mo, without any radiol. response or improvement in the delay before symptomatic progression of the disease. The monthly cost of sorafenib is a little more than 5,000 euros. It is now crucial to evaluate the potential role of sorafenib in adjuvant therapy after liver resection or radiofrequency ablation of hepatocarcinoma. The CHU of Liege is taking part to a randomized, multicentric study evaluating the use of sorafenib after liver resection or radiofrequency ablation for hepatocarcinoma. Another future evaluation could be the association of sorafenib with other antitumoral agents.
IT 284461-73-0, Sorafenib 475207-59-1, Nexavar
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(palliative management of hepatocarcinoma with sorafenib)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3




CM 2

CRN 104-15-4
CMF C7 H8 O3 S



L12 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2009:1629506 CAPLUS
DN 153:162840
TI Platelet count less than SHARP: what does a case series reveal?
AU Saif, M. Wasif
CS Section of Medical Oncology, Yale University School of Medicine, New Haven, CT, 06520, USA
SO Expert Opinion on Drug Safety (2010), 9(1), 1-8
CODEN: EODSA9; ISSN: 1474-0338
PB Informa Healthcare
DT Journal; General Review
LA English
AB A review. Hepatocellular carcinoma (HCC) is increasing in nos. worldwide, and no effective systemic treatment existed for advanced HCC until SHARP (Sorafenib in HCC Assessment Randomized Protocol) study proved sorafenib (Nexavar, Bayer Pharmaceuticals, Wayne, NJ, USA) prolonged survival vs. placebo. Child-Pugh class A liver function and a platelet count of ≥ 60,000/mm3 were among the inclusion criteria for SHARP. No safety data in patients with < 60,000/mm3 of platelets are present. Thrombocytopenia is one of the most frequent challenges faced in patients with chronic liver diseases. We report a series of three patients with HCC and platelet count < 60,000/mm3 who were successfully treated with sorafenib with no complications. We describe the current data on sorafenib and challenges faced in patients with HCC. In addition, we emphasize the need for informed consent when facing factors that predispose to bleeding (esophageal varices, coagulopathy and thrombocytopenia), possible band ligation before the start of sorafenib, careful clin. monitoring and discontinuation of sorafenib when major bleeding occurs.
IT 475207-59-1, Nexavar
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nexavar was safe and effective but reduced platelet count in patient with hepatocellular carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2009:324660 CAPLUS
DN 151:235838
TI Sorafenib for the treatment of unresectable hepatocellular carcinoma
AU Kane, Robert C.; Farrell, Ann T.; Madabushi, Rajanikanth; Booth, Brian; Chattopadhyay, Somesh; Sridhara, Rajeshwari; Justice, Robert; Pazdur, Richard
CS Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA
SO Oncologist (2009), 14(1), 95-100
CODEN: OCOLF6; ISSN: 1083-7159
PB AlphaMed Press
DT Journal
LA English
AB Purpose. To describe the U.S. Food and Drug Administration (FDA) review and approval of sorafenib (Nexavar; Bayer Pharmaceuticals Corp., Montville, NJ, and Onyx Pharmaceuticals Corp., Emeryville, CA), an oral kinase inhibitor, for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Exptl. Design. The FDA independently analyzed an international, double-blind, placebo-controlled trial comparing the effect of best supportive care plus sorafenib or matching placebo on overall survival. Eligible patients had unresectable, biopsy-proven HCC and had not received prior systemic therapy. Results. Among the 602 randomized patients (placebo, 303; sorafenib, 299), baseline characteristics were well balanced, and 97% were Child-Pugh score A. HCC was "advanced" in 70% overall, as defined by extrahepatic metastases or by tumor radiog. visible in venous structures outside the liver. Underlying liver diseases included hepatitis B (18%), hepatitis C (28%), and alc.-related (26%). The trial was stopped following a prespecified second interim anal. showing a statistically significant survival advantage for sorafenib [median, 10.7 vs 7.9 mo; hazard ratio, 0.69 (95% confidence interval, (0.55, 0.87)), p = 0.00058]. Adverse events in sorafenib-treated patients included diarrhea in 55% (grade 3, 10%), hand-foot syndrome in 21% (grade 3,8%), rash in 19% (grade 3,1%), and cardiac ischemia or infarction in 2.7% (vs. 1.3% for placebo). On sorafenib, treatment-emergent hypertension occurred in 9% of patients (placebo, 4%) and was grade 3 in 4% (placebo, 1%); elevated serum lipase occurred in 40% (placebo, 37%); hypophosphatemia occurred in 35% (placebo, 11%). Conclusions. Sorafenib is the first systemic therapy to demonstrate a survival benefit in a randomized trial for unresectable HCC and has received FDA approval for this indication.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sorafenib for treating unresectable hepatocellular carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2008:1542770 CAPLUS
DN 151:48669
TI Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial
AU Cheng, Ann-Lii; Kang, Yoon-Koo; Chen, Zhendong; Tsao, Chao-Jung; Qin, Shukui; Kim, Jun Suk; Luo, Rongcheng; Feng, Jifeng; Ye, Shenglong; Yang, Tsai-Sheng; Xu, Jianming; Sun, Yan; Liang, Houjie; Liu, Jiwei; Wang, Jiejun; Tak, Won Young; Pan, Hongming; Burock, Karin; Zou, Jessie; Voliotis, Dimitrios; Guan, Zhongzhen
CS National Taiwan University Hospital, Taipei, Taiwan
SO Lancet Oncology (2009), 10(1), 25-34
CODEN: LOANBN; ISSN: 1470-2045
PB Elsevier Ltd.
DT Journal
LA English
AB Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important etiol. factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific population is thus important. We did a multinational phase III, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of sorafenib in patients from the Asia-Pacific region with advanced (unresectable or metastatic) hepatocellular carcinoma. Between Sept 20, 2005, and Jan 31, 2007, patients with hepatocellular carcinoma who had not received previous systemic therapy and had Child-Pugh liver function class A, were randomly assigned to receive either oral sorafenib (400 mg) or placebo twice daily in 6-wk cycles, with efficacy measured at the end of each 6-wk period. Eligible patients were stratified by the presence or absence of macroscopic vascular invasion or extrahepatic spread (or both), Eastern Cooperative Oncol. Group performance status, and geog. region. Randomization was done centrally and in a 2:1 ratio by means of an interactive voice-response system. There was no predefined primary endpoint; overall survival, time to progression (TTP), time to symptomatic progression (TTSP), disease control rate (DCR), and safety were assessed. Efficacy analyses were done by intention to treat. This trial is registered with, number Two hundred and seventy-one 271 patients from 23 centers in China, South Korea, and Taiwan were enrolled in the study. Of these, 226 patients were randomly assigned to the exptl. group (n=150) or to the placebo group (n=76). Median overall survival was 6.5 mo (95% CI 5.56-7.56) in patients treated with sorafenib, compared with 4.2 mo (3.75-5.46) in those who received placebo (hazard ratio [HR] 0.68 [95% CI 0.50-0.93]; p=0.014). Median TTP was 2.8 mo (2.63-3.58) in the sorafenib group compared with 1.4 mo (1.35-1.55) in the placebo group (HR 0.57 [0.42-0.79]; p=0.0005). The most frequently reported grade 3/4 drug-related adverse events in the 149 assessable patients treated with sorafenib were hand-foot skin reaction (HFSR; 16 patients [10.7%]), diarrhea (nine patients [6.0%]), and fatigue (five patients [3.4%]). The most common adverse events resulting in dose redns. were HFSR (17 patients [11.4%]) and diarrhea (11 patients [7.4%]); these adverse events rarely led to discontinuation. Sorafenib is effective for the treatment of advanced hepatocellular carcinoma in patients from the Asia-Pacific region, and is well tolerated. Taken together with data from the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) trial, sorafenib seems to be an appropriate option for the treatment of advanced hepatocellular carcinoma. Funding: Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.

IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(sorafenib was well tolerated and effective in treatment of patient with metastatic hepatocellular carcinoma in Asia-Pacific region)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




OSC.G 102 THERE ARE 102 CAPLUS RECORDS THAT CITE THIS RECORD (102 CITINGS)
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2008:798022 CAPLUS
DN 149:263859
TI Dissecting and Targeting the Growth Factor-Dependent and Growth Factor-Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma
AU Ammoun, Sylwia; Flaiz, Christine; Ristic, Natalia; Schuldt, Jennifer; Hanemann, C. Oliver
CS Clinical Neurobiology, Peninsula College for Medicine and Dentistry, Plymouth, PL6 8BU, UK
SO Cancer Research (2008), 68(13), 5236-5245
CODEN: CNREA8; ISSN: 0008-5472
PB American Association for Cancer Research
DT Journal
LA English
AB Schwannomas are tumors of the nervous system that occur sporadically and in patients with the cancer predisposition syndrome neurofibromatosis type 2 (NF2). Schwannomas and all NF2-related tumors are caused by loss of the tumor suppressor merlin. Using our human in vitro model for schwannoma, we analyzed extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT signaling pathways, their upstream growth factor receptors, and their role in schwannoma cell proliferation and adhesion to find new systemic therapies for these tumors that, to date, are very difficult to treat. We show here that human primary schwannoma cells show an enhanced basal Raf/mitogen-activated protein/ERK kinase/ERK1/2 pathway activity compared with healthy Schwann cells. Due to a strong and prolonged activation of platelet-derived growth factor receptor β (PDGFRβ), which is highly overexpressed, ERK1/2 and AKT activation was further increased in schwannoma, leading to increased proliferation. Using specific inhibitors, we discovered that ERK1/2 activation involves the integrin/focal adhesion kinase/Src/Ras signaling cascades and PDGFRβ-mediated ERK1/2 activation is triggered through the phosphatidylinositol 3-kinase/protein kinase C/Src/c-Raf pathway. Due to the complexity of signals leading to schwannoma cell proliferation, potential new therapeutic agents should target several signaling pathways. The PDGFR and c-Raf inhibitor sorafenib (BAY 43-9006; Bayer Pharmaceuticals), currently approved for treatment of advanced renal cell cancer, inhibits both basal and PDGFRβ-mediated ERK1/2 and AKT activity and decreases cell proliferation in human schwannoma cells, suggesting that this drug constitutes a promising tool to treat schwannomas. We conclude that our schwannoma in vitro model can be used to screen for new therapeutic targets in general and that sorafenib is possible candidate for future clin. trials.
IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006; growth factor-dependent and growth factor-independent ERK kinase pathway in human schwannoma)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
RE.CNT 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471132 CAPLUS
DN 147:132413
TI Looking ahead in renal cell carcinoma: integrating new agents in the armamentarium of the urologist
AU Patard, Jean-Jacques
CS Rennes University Hospital, Rennes, Fr.
SO European Urology, Supplements (2007), 6(7), 505-509
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB A review. Urologists play a pivotal role in many aspects of the care of patients with renal cell carcinoma (RCC). However, until recently, in some European countries, they have rarely been involved in the systemic treatment of this disease or in the design of clin. trials. This is undoubtedly set to change with the emergence of new oral, molecularly targeted therapies for RCC. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) is one such therapy, which has already been shown to be efficacious and well tolerated for the treatment of RCC. Although targeted agents show great promise for the treatment of RCC, their precise role in the treatment of metastatic disease, and in adjuvant and neoadjuvant settings has yet to be defined. Drawing from their extensive experience of RCC, urologists will be instrumental in the design and application of clin. studies to define the role of targeted therapies in all settings of RCC and, ultimately, to integrate targeted therapies into clin. practice. Through increased understanding of the mol. pathways involved in RCC, research into diagnostic and prognostic markers, and commitment to clin. trials, urologists can be at the forefront of this progress.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mol. targeted therapy with Nexavar was effective and well tolerated in renal cell carcinoma patient)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471131 CAPLUS
DN 147:132412
TI New perspectives: an oral multikinase inhibitor in patients with advanced RCC
AU Escudier, Bernard
CS Institut Gustave-Roussy, Paris, Fr.
SO European Urology, Supplements (2007), 6(7), 499-504
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB A review. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) is an oral multikinase inhibitor that may provide dual action by inhibiting tumor cell proliferation and angiogenesis. Sorafenib was recently evaluated in the largest phase 3, randomized trial ever conducted in renal cell carcinoma (RCC): Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET). In TARGET, sorafenib significantly increased progression-free survival vs. placebo, which led to a change in the study protocol allowing patients in the placebo arm of the trial to cross over to receive sorafenib. At the time of crossover, sorafenib improved overall survival by 39% compared with placebo (hazard ratio = 0.72; 95% confidence interval 0.54-0.94; p = 0.02, not significant as per O'Brien-Fleming threshold for statistical significance: p = 0.0005). Sorafenib continued to show a trend towards improved overall survival at a subsequent anal. 6 mo post-crossover. Importantly, 84% of sorafenib-treated patients achieved investigator-assessed stable disease or better compared with 55% of placebo recipients. Sorafenib was well tolerated, had a manageable side-effect profile, and offered benefit with no compromise in quality of life. The data from the phase 3 TARGET study provided further evidence that sorafenib may be effective in a wide range of patients with advanced RCC. Clin. trials are planned to assess the potential of sorafenib as combination therapy and in the adjuvant setting.
IT 475207-59-1, Nexavar
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oral multikinase inhibitor Nexavar was well tolerated and increased progression-free as well as overall survival in patient with advanced renal cell carcinoma)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2007:471130 CAPLUS
DN 147:132411
TI Adjuvant therapy in renal cell carcinoma: where are we?
AU Eisen, Tim
CS University of Cambridge, Cambridge, UK
SO European Urology, Supplements (2007), 6(7), 492-498
CODEN: EUSUAU; ISSN: 1569-9056
PB Elsevier B.V.
DT Journal; General Review
LA English
AB This review summarizes available data and describes planned clin. trials designed to evaluate the potential of targeted agents as adjuvant therapy for renal cell carcinoma (RCC). Advanced RCC is refractory to standard cytotoxic chemotherapy, and clin. trials of adjuvant cytokine therapy in this therapeutic setting have not yet demonstrated clear evidence of clin. benefit. However, molecularly targeted therapies may offer a new approach for adjuvant therapy of this disease. Sorafenib (Nexavar; Bayer Healthcare, West Haven, CT, USA) and sunitinib (Sutent; Pfizer Inc, New York, NY, USA) are candidates for adjuvant therapy, because they are efficacious in the treatment of metastatic RCC and have side-effect profiles that can usually be well managed during long-term administration. The clin. benefit and tolerability of these agents as adjuvant therapies are being investigated in three ongoing phase 3 trials: ASSURE (adjuvant sorafenib or sunitinib in unfavorable renal cell carcinoma; Eastern Cooperative Oncol. Group 2805), STAR (sunitinib trial in adjuvant renal cancer) and SORCE (a phase 3, randomized, double-blind, controlled study comparing sorafenib with placebo in patients with resected primary renal cell carcinoma at high or intermediate risk of relapse). The results of these studies will address important clin. and translational questions, the answers to which may help define future treatment strategies and guide treatments towards the most appropriate patients.
IT 475207-59-1, Nexavar
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(adjuvant therapy with Nexavar might be effective in renal cell carcinoma patient)
RN 475207-59-1 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S



OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2006:1258840 CAPLUS
DN 146:219796
TI Sorafenib for the treatment of renal cell carcinoma
AU Hughes, Caren L.; Tan, Winston W.; Ferrone, Marcus
CS Oncology Specialty Resident, Division of Pharmacy, MD Anderson Cancer Center, The University of Texas, Houston, TX, USA
SO Journal of Pharmacy Technology (2006), 22(5), 281-288
CODEN: JPTEEB; ISSN: 8755-1225
PB Harvey Whitney Books Co.
DT Journal; General Review
LA English
AB A review. Objective: To summarize the pharmacol., development, and clin. application of sorafenib, a specific tyrosine kinase and vascular growth factor inhibitor, for the treatment of renal cell carcinoma (RCC). Data Sources: Clin. literature, including both primary studies and review articles, was obtained by searching MEDLINE (1966-May 2006), using the search terms BAY 43-9006, sorafenib, renal cell carcinoma, and tyrosine kinase inhibitor. Addnl. information was supplied by the manufacturer, Bayer HealthCare Pharmaceuticals. Study Selection and Data Extraction: Review articles, abstrs., and clin. studies related to sorafenib were analyzed. An evaluation of the research exploring sorafenib as a potential therapy for RCC was conducted. Relevant information was then selected and is reviewed in this article. Data Synthesis: Knowledge of the cellular abnormalities that can cause solid tumors has led to the development of medications that block these pathways. Sorafenib is an oral tyrosine kinase inhibitor that both blocks the Raf kinase pathway and inhibits vascular growth factors. Phase I and II trials have demonstrated that sorafenib has activity against RCC. Dermatol. reactions (rash, desquamation), fatigue, and hypertension have been the most commonly seen treatment-related adverse events. Sorafenib received FDA approval in Dec. 2005 for treatment of advanced RCC. Conclusions: Soraferib is a novel oral tyrosine kinase inhibitor effective in the treatment of RCC.
IT 284461-73-0, Sorafenib
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phase I and II trial showed that tyrosine kinase inhibitor sorafenib blocked Raf kinase pathway and inhibited vascular growth factor responsible for angiogenesis and tumor growth in patient with renal cell carcinoma)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2006:1020380 CAPLUS
DN 145:431615
TI Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
AU Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan
CS Department of Cancer Research, Bayer Pharmaceuticals Corp., West Haven, CT, 06516, USA
SO Nature Reviews Drug Discovery (2006), 5(10), 835-844
CODEN: NRDDAG; ISSN: 1474-1776
PB Nature Publishing Group
DT Journal; General Review
LA English
AB A review. Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received .apprx.5 years after the initiation of the first Phase I trial.
IT 284461-73-0, Sorafenib
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(discovery and development of sorafenib, a multikinase inhibitor for treating cancer)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




OSC.G 198 THERE ARE 198 CAPLUS RECORDS THAT CITE THIS RECORD (199 CITINGS)
RE.CNT 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2011 ACS on STN
AN 2003:736198 CAPLUS
DN 139:301125
TI BAY-43-9006(Bayer/Onyx)
AU Lee, John T.; McCubrey, James A.
CS Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, NC, 27858-4353, USA
SO Current Opinion in Investigational Drugs (Thomson Current Drugs) (2003), 4(6), 757-763
CODEN: COIDAZ; ISSN: 1472-4472
PB Thomson Current Drugs
DT Journal; General Review
LA English
AB A review. Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by Feb. 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.
IT 284461-73-0, BAY 43-9006
RL: ADV (Adverse effect, including toxicity); DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BAY 43-9006 for treatment of cancer patients)
RN 284461-73-0 CAPLUS
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




OSC.G 58 THERE ARE 58 CAPLUS RECORDS THAT CITE THIS RECORD (58 CITINGS)
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s raf or tumor or cancer or carcinoma or adenoma or leukemia
         10045 RAF
        578994 TUMOR
        490811 CANCER
        241830 CARCINOMA
         15739 ADENOMA
        138113 LEUKEMIA
L13    1042738 RAF OR TUMOR OR CANCER OR CARCINOMA OR ADENOMA OR LEUKEMIA

=> s l10 and l13
L14       1337 L10 AND L13

=> => d his

     (FILE 'HOME' ENTERED AT 07:44:56 ON 18 JAN 2011)

     FILE 'REGISTRY' ENTERED AT 07:46:14 ON 18 JAN 2011
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3             43 S L2 SSS SAM
L4                SCREEN 1840
L5                SCREEN 2016 OR  2026 OR  1841 OR  2039 OR  2040 OR  2045 OR  20
L6                STRUCTURE UPLOADED
L7                QUE L6 AND L4 NOT L5
L8              4 S L7 SSS SAM
L9             78 S L7 SSS FUL

     FILE 'CAPLUS' ENTERED AT 07:54:26 ON 18 JAN 2011
L10         1515 S L9
L11        10038 S BAYER?
L12           11 S L10 AND L11
L13      1042738 S RAF OR TUMOR OR CANCER OR CARCINOMA OR ADENOMA OR LEUKEMIA
L14         1337 S L10 AND L13

     FILE 'USPATFULL' ENTERED AT 07:58:05 ON 18 JAN 2011

=> s l9
L15         335 L9

=> d l15 301-335 bib,ab,hitstr
```

L15 ANSWER 301 OF 335 USPATFULL on STN
AN 2005:247130 USPATFULL
TI Compositions and methods to increase the effect of a neurotoxin treatment
IN David, Nathaniel E., San Francisco, CA, UNITED STATES
PA VVII NewCo 2003, Inc., Menlo Park, CA, UNITED STATES (U.S. corporation)
PI US 20050214325 A1 20050929
AI US 2004-810391 A1 20040326 (10)
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 94304-1050, US
CLMN Number of Claims: 40
ECL Exemplary Claim: 1
DRWN 1 Drawing Page(s)
LN.CNT 1120
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses compositions and methods for enhancing the effect (e.g., duration) of a neurotoxin treatment. The compositions herein include neurotoxins and neuron growth inhibitors. Such compositions are administered locally to treat or prevent conditions, such as dermatological conditions, urological conditions, thyroid conditions, optical conditions, and neurological conditions.
IT 284461-73-0, BAY-43-9006
(compns. and methods to increase effect of neurotoxin treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 302 OF 335 USPATFULL on STN
AN 2005:183990 USPATFULL
TI JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
IN Mohapatra, Shyam S., Tampa, FL, UNITED STATES
PI US 20050159385 A1 20050721
AI US 2004-18954 A1 20041220 (11)
PRAI US 2003-531052P 20031219 (60)
DT Utility
FS APPLICATION
LREP SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
CLMN Number of Claims: 20
ECL Exemplary Claim: 1
DRWN 17 Drawing Page(s)
LN.CNT 2773
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection
IT 284461-73-0, BAY 43-9006
(JAK/STAT inhibitors and MAPK/ERK inhibitors for respiratory syncytial virus infection treatment)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 303 OF 335 USPATFULL on STN
AN 2005:171786 USPATFULL
TI IAP nucleobase oligomers and oligomeric complexes and uses thereof
IN LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
PI US 20050148535 A1 20050707
AI US 2004-975974 A1 20041028 (10)
PRAI US 2003-516192P 20031030 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 48
ECL Exemplary Claim: 1
DRWN 15 Drawing Page(s)
LN.CNT 3022
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides nucleobase oligomers and oligomer complexes that inhibit expression of an IAP polypeptide, and methods for using them to induce apoptosis in a cell. The nucleobase oligomers and oligomer complexes of the present invention may also be used to form pharmaceutical compositions. The invention also features methods for enhancing apoptosis in a cell by administering a nucleobase oligomer or oligomer complex of the invention in combination with a chemotherapeutic or chemosensitizing agent.
IT 284461-73-0, BAY-43-9006
(human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 304 OF 335 USPATFULL on STN
AN 2005:138567 USPATFULL
TI Methods and reagents for the treatment of proliferative diseases
IN LaCasse, Eric, Ottawa, CANADA
McManus, Daniel, Ottawa, CANADA
Durkin, Jon P., Montreal, CANADA
PI US 20050119217 A1 20050602
AI US 2004-975790 A1 20041028 (10)
PRAI US 2003-516263P 20031030 (60)
DT Utility
FS APPLICATION
LREP CLARK & ELBING LLP, 101 FEDERAL STREET, BOSTON, MA, 02110, US
CLMN Number of Claims: 58
ECL Exemplary Claim: 1
DRWN 34 Drawing Page(s)
LN.CNT 5896
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention features methods, compositions, and kits for treating a patient having a proliferative disease.
IT 284461-73-0, BAY-43-9006
(sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with chemotherapeutic agent)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 305 OF 335 USPATFULL on STN
AN 2005:137954 USPATFULL
TI Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
IN Aoki, Yuko, Kanagawa, JAPAN
Hasegawa, Kiyoshi, Kanagawa, JAPAN
Ishii, Nobuya, Kanagawa, JAPAN
Mori, Kazushige, Kanagawa, JAPAN
PI US 20050118600 A1 20050602
AI US 2003-507389 A1 20020313 (10)
WO 2002-JP2354 20020313
DT Utility
FS APPLICATION
LREP FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110, US
CLMN Number of Claims: 31
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2028
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Based on drug sensitivity data and extensive gene expression data, a model was constructed by multivariate analysis with the partial least squares method type 1. Further, the model was optimized using modeling power and genetic algorithm. Thereby, the degree of contribution of the respective genes to drug sensitivity was determined to select genes with a high degree of contribution. In addition, the levels of gene expression in specimens were analyzed, and then the drug sensitivity was predicted based on the model. The predicted values agreed well with those drug sensitivity values determined experimentally. The drug sensitivity-predicting method provided by the present invention enables assessment of the effectiveness of a drug prior to administration using small quantities of specimens associated with diseases such as cancer. Since this enables the selection of the most suitable drug for each patient, the present invention is very useful in improving a patient's quality of life (QOL).
IT 284461-73-0, BAY 439006
(method for selecting antitumor drug sensitivity-determining factors and predicting antitumor drug sensitivity using the selected factors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 306 OF 335 USPATFULL on STN
AN 2005:69562 USPATFULL
TI Diaryl ureas for diseases mediated by PDGFR
IN Wilhelm, Scott, Orange, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Ladouceur, Gaetan, Guilford, CT, UNITED STATES
Lynch, Mark, Madison, CT, UNITED STATES
Scott, William, Guilford, CT, UNITED STATES
PI US 20050059703 A1 20050317
AI US 2004-848567 A1 20040519 (10)
PRAI US 2004-556062P 20040325 (60)
US 2003-520399P 20031117 (60)
US 2003-471735P 20030520 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 74
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1901
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides methods for treating and/or preventing conditions and diseases in humans and other mammals that are associated with and/or mediated by signal transduction pathways comprising platelet-derived growth factor receptor (PDGFR) by administering diaryl ureas of Formula I. The present invention also provides devices and methods for treating, ameliorating, preventing, or modulating restenosis following angioplastic surgery or other invasive procedures that affect or injure the vascular system, and graft rejection following transplantation of a donor tissue into a host, where a stent or other omplantable device comprises an effective amount of diaryl ureas of Formula I.
IT 284461-73-0 284461-74-1 284462-18-6
475207-59-1 583840-03-3 583840-04-4
(diaryl ureas for prevention and/or treatment of diseases mediated by platelet-derived growth factor receptor)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)




RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



L15 ANSWER 307 OF 335 USPATFULL on STN
AN 2005:69531 USPATFULL
TI Novel farnesyl protein transferase inhibitors as antitumor agents
IN Zhu, Hugh Y., Scotch Plains, NJ, UNITED STATES
Cooper, Alan B., West Caldwell, NJ, UNITED STATES
Desai, Jagdish A., Monroe Township, NJ, UNITED STATES
Wang, James J-S, Westfield, NJ, UNITED STATES
Rane, Dinanath F., Morganville, NJ, UNITED STATES
Doll, Ronald J., Convent Station, NJ, UNITED STATES
Njoroge, F. George, Warren, NJ, UNITED STATES
Girijavallabhan, Viyyoor M., Parsipanny, NJ, UNITED STATES
PA SCHERING CORPORATION (U.S. corporation)
PI US 20050059672 A1 20050317
US 7557107 B2 20090707
AI US 2004-911340 A1 20040804 (10)
PRAI US 2003-493269P 20030807 (60)
US 2003-498509P 20030828 (60)
DT Utility
FS APPLICATION
LREP SCHERING-PLOUGH CORPORATION, PATENT DEPARTMENT (K-6-1, 1990), 2000 GALLOPING HILL ROAD, KENILWORTH, NJ, 07033-0530
CLMN Number of Claims: 120
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4090
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are novel tricyclic compounds of the formula: ##STR1##

and a pharmaceutically acceptable salts or solvates thereof. The compounds are useful for inhibiting farnesyl protein transferase. Also disclosed are pharmaceutical compositions comprising the compounds of formula (I). Also disclosed are uses of the compounds of formula (I) for the manufacture of a medicament for the treatment of cancer.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of piperazinylbenzocycloheptapyridines as farnesyl protein transferase inhibitors useful as antitumor agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 308 OF 335 USPATFULL on STN
AN 2005:56618 USPATFULL
TI BRAF mutation T1796A in thyroid cancers
IN Sidransky, David, Baltimore, MD, UNITED STATES
Cohen, Yoram, Baltimore, MD, UNITED STATES
Zhao, Ming, Clarksville, MD, UNITED STATES
PA The Johns Hopkins University, Baltimore, MD, UNITED STATES, 21218 (U.S. corporation)
PI US 20050048533 A1 20050303
US 7378233 B2 20080527
AI US 2004-821203 A1 20040409 (10)
PRAI US 2003-462046P 20030412 (60)
DT Utility
FS APPLICATION
LREP BANNER & WITCOFF, 1001 G STREET N W, SUITE 1100, WASHINGTON, DC, 20001
CLMN Number of Claims: 24
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 1021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The BRAF gene has been found to be activated by mutation in human cancers, predominantly in malignant melanoma. We tested 476 primary tumors, including 214 lung, 126 head and neck, 54 thyroid, 27 bladder, 38 cervical, and 17 prostate cancers, for the BRAF T1796A mutation by polymerase chain reaction (PCR)-restriction enzyme analysis of BRAF exon 15. In 24 (69%) of the 35 papillary thyroid carcinomas examined, we found a missense thymine (T)→adenine (A) transversion at nucleotide 1796 in the BRAF gene (T1796A). The T1796A mutation was detected in four lung cancers and in six head and neck cancers but not in bladder, cervical, or prostate cancers. Our data suggest that activating BRAF mutations may be an important event in the development of papillary thyroid cancer. Moreover, BRAF mutation reliably predicts a poor prognosis for papillary thyroid carcinomas.
IT 284461-73-0, BAY 43-9006
(detection of BRAF transversion mutation for diagnosis of malignant thyroid cancer and uses of Ras-Raf-MAPK or Raf/MEK/ERK signaling pathway inhibitor in treating thyroid cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 309 OF 335 USPATFULL on STN
AN 2005:44298 USPATFULL
TI Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Boyer, Stephen, Fairfield, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Scott, William J., Guildford, CT, UNITED STATES
Burke, Jennifer, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Miranda, Karl, North Haven, CT, UNITED STATES
Raudenbush, Brian, Charlton, MA, UNITED STATES
Redman, Aniko, Derby, CT, UNITED STATES
Shao, Jianxing, Acton, MA, UNITED STATES
Su, Ning, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
Zhu, Qingming, West Haven, CT, UNITED STATES

Claims contain a bicyclic group

PI US 20050038031 A1 20050217
AI US 2004-788426 A1 20040301 (10)
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 30
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4157
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L15 ANSWER 310 OF 335 USPATFULL on STN
AN 2005:38118 USPATFULL
TI 2-Oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatory disorders
IN Boyer, Stephen, Fairfield, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Scott, William J., Guildford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Jones, Benjamin, Hamden, CT, UNITED STATES
Wang, Gan, Wallingford, CT, UNITED STATES
PI US 20050032798 A1 20050210
AI US 2004-788405 A1 20040301 (10)
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2600
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 311 OF 335 USPATFULL on STN
AN 2004:299960 USPATFULL
TI Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
IN Scott, William J., Guilford, CT, UNITED STATES
Dumas, Jacques, Bethany, CT, UNITED STATES
Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Lee, Wendy, Hamden, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Phillips, Barton, New Haven, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Fan, Jianmei, Hamden, CT, UNITED STATES
Raudenbush, Brian, Charlton, MA, UNITED STATES
Redman, Aniko, Derby, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
Zhu, Qingming, West Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
PI US 20040235829 A1 20041125
US 7557129 B2 20090707 no ODP
AI US 2004-788029 A1 20040227 (10)
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 63
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2828
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 312 OF 335 USPATFULL on STN
AN 2004:292848 USPATFULL
TI Substituted pyridine derivatives useful in the treatment of cancer and other disorders
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Chen, Yuanwei, North Haven, CT, UNITED STATES
Adnane, Lila, Madison, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Verma, Sharad, New Haven, CT, UNITED STATES
Chen, Jianqing, New Haven, CT, UNITED STATES
Chen, Zhi, Hamden, CT, UNITED STATES
Yi, Lin, Milford, CT, UNITED STATES
PI US 20040229937 A1 20041118
AI US 2004-789446 A1 20040301 (10) ABN
PRAI US 2003-450323P 20030228 (60)
US 2003-450324P 20030228 (60)
US 2003-450348P 20030228 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2564
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to novel diaryl ureas, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and angiogenesis disorders, as a sole agent or in combination with cytotoxic therapies.
IT 284461-73-0, Bay 43-9006
(coadministration; preparation of ureidophenoxycyanopyridines as anticancer drugs)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 313 OF 335 USPATFULL on STN
AN 2004:165963 USPATFULL
TI Method for treating diseases associated with abnormal kinase activity
IN Lyons, John, Moraga, CA, UNITED STATES
Rubinfeld, Joseph, Danville, CA, UNITED STATES
PI US 20040127453 A1 20040701
US 6998391 B2 20060214
AI US 2002-206854 A1 20020726 (10)
RLI Continuation-in-part of Ser. No. US 2002-71849, filed on 7 Feb 2002, PENDING
DT Utility
FS APPLICATION
LREP WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050
CLMN Number of Claims: 66
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1941
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods are provided for treating diseases associated with abnormal activity of kinases. The method comprises: administering a DNA methylation inhibitor to the patient in therapeutically effective amount; and administering a kinase inhibitor to the patient in therapeutically effective amount, such that the in vivo activity of the kinase is reduced relative to that prior to the treatment. The method can be used to treat cancer associated with abnormal activity of kinases such as phosphatidylinositol 3'-kinase (PI3K), protein kinases including serine/threonine kinases such as Raf kinases, protein kinase kinases such as MEK, and tyrosine kinases such as those in the epidermal growth factor receptor family (EGFR), platelet-derived growth factor receptor family (PDGFR), vascular endothelial growth factor receptor (VEGFR) family, nerve growth factor receptor family (NGFR), fibroblast growth factor receptor family (FGFR) insulin receptor family, ephrin receptor family, Met family, Ror family, c-kit family, Src family, Fes family, JAK family, Fak family, Btk family, Syk/ZAP-70 family, and Abl family.
IT 284461-73-0, BAY 43-9006
(Raf kinase inhibitor; treating diseases associated with abnormal tyrosine kinase activity by administering DNA methylation inhibitors and tyrosine kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 314 OF 335 USPATFULL on STN
AN 2003:330550 USPATFULL
TI Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
IN Carter, Christopher A., Guilford, CT, UNITED STATES
Gibson, Neil, East Northport, NY, UNITED STATES
Hibner, Barbara, Madison, CT, UNITED STATES
Humphrey, Rachel W., Woodbridge, CT, UNITED STATES
Trail, Pamela, Madison, CT, UNITED STATES
Vincent, Patrick W., Cheshire, CT, UNITED STATES
Zhai, Yifan, Guilford, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, UNITED STATES (U.S. corporation)
PI US 20030232765 A1 20031218
AI US 2002-308187 A1 20021203 (10) ABN
PRAI US 2001-334609P 20011203 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 1005
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to aryl urea compounds in combination with cytotoxic or cytostatic agents for use in treating raf kinase mediated diseases such as cancer.
IT 475207-59-1
(aryl urea compds. in combination with other cytostatic or cytotoxic agents for treating human cancers and other raf kinase-mediated diseases)
RN 475207-59-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 284461-73-0
CMF C21 H16 Cl F3 N4 O3




CM 2

CRN 104-15-4

CMF C7 H8 O3 S



L15 ANSWER 315 OF 335 USPATFULL on STN
AN 2003:307010 USPATFULL
TI Aryl ureas as kinase inhibitors
IN Dumas, Jacques, Orange, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Chien, Du-Shieng, Guilford, CT, UNITED STATES
Nassar, Ala, Milford, CT, UNITED STATES
Lee, Wendy, Hamden, CT, UNITED STATES
Bjorge, Susan, Milford, CT, UNITED STATES
Musza, Laszlo L., Guilford, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, UNITED STATES (U.S. corporation)
PI US 20030216446 A1 20031120
AI US 2003-361859 A1 20030211 (10)
PRAI US 2002-354937P 20020211 (60)
now allowed
N-oxide compounds
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 73
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1856
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-carbamoyl(4-pyridyloxy)phenyl]urea 284462-18-6P 583840-03-3P 583840-04-4P 583840-09-9P
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



RN 583840-09-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-05-5P 583840-06-6P 583840-07-7P
583840-08-8P
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
RN 583840-05-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (CA INDEX NAME)



RN 583840-06-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-07-7 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(hydroxymethyl)-, 1-oxide (CA INDEX NAME)



RN 583840-08-8 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



IT 284461-73-0P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)(4-pyridyloxy)phenyl]urea
(preparation of aryl ureas for therapeutic use as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 316 OF 335 USPATFULL on STN
AN 2003:306960 USPATFULL
TI Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
IN Dumas, Jacques, Bethany, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
PA BAYER CORPORATION, Pittsburgh, PA (U.S. corporation)
PI US 20030216396 A1 20031120
AI US 2003-361850 A1 20030211 (10) ABN
PRAI US 2002-354935P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to urea compounds containing a pyridine, quinoline, or isoquinoline functionality which is oxidized at the nitrogen heteroatom and which are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.
IT 284461-73-0
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




IT 284461-74-1P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



IT 583840-03-3P 583840-04-4P
(preparation of aryl ureas containing pyridine, quinoline and isoquinoline N-oxide functionality as kinase inhibitors)
RN 583840-03-3 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-, 1-oxide (CA INDEX NAME)



RN 583840-04-4 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-, 1-oxide (CA INDEX NAME)



L15 ANSWER 317 OF 335 USPATFULL on STN
AN 2003:294854 USPATFULL
TI OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 20030207872 A1 20031106
AI US 2002-42226 A1 20020111 (10) ABN
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P 284461-82-1P
284461-88-7P 284462-04-0P 284462-05-1P
284462-17-5P 284462-18-6P 284462-21-1P
604813-04-9P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[[3-[5-(2-dimethylaminoethyl)carbamoyl]pyridyl]oxy]phenyl]urea
(preparation of ω-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors for treating raf-mediated diseases such as cancerous cell growth)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 604813-04-9 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



L15 ANSWER 318 OF 335 USPATFULL on STN
AN 2003:294852 USPATFULL
TI Aryl ureas with angiogenisis inhibiting activity
IN Dumas, Jacques, Orange, CT, UNITED STATES
Scott, William J., Guilford, CT, UNITED STATES
Elting, James, Madison, CT, UNITED STATES
Hatoum-Makdad, Holia, Hamden, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (U.S. corporation)
PI US 20030207870 A1 20031106
US 7838541 B2 20101123
AI US 2003-361858 A1 20030211 (10)
PRAI US 2002-354950P 20020211 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 32
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2356
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to methods of using aryl ureas to treat diseases mediated by the VEGF induced signal transduction pathway characterized by abnormal angiogenesis or hyperpermeability processes.
IT 284461-73-0P 284461-74-1P
(preparation of aryl ureas with angiogenesis inhibiting activity)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



L15 ANSWER 319 OF 335 USPATFULL on STN
AN 2003:271082 USPATFULL
TI Antibodies that immunospecifically bind to trail receptors
IN Salcedo, Theodora, Montgomery Village, MD, UNITED STATES
Ruben, Steven M., Brookeville, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
Albert, Vivian R., Rockville, MD, UNITED STATES
Dobson, Claire, Cambridge, UNITED KINGDOM
Vaughan, Tristan, Cambridge, UNITED KINGDOM
PA Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S. corporation)
PI US 20030190685 A1 20031009
US 7064189 B2 20060620
AI US 2002-139785 A1 20020507 (10)
PRAI US 2001-293473P 20010525 (60)
US 2001-294981P 20010604 (60)
US 2001-309176P 20010802 (60)
US 2001-323807P 20010921 (60)
US 2001-327364P 20011009 (60)
US 2001-331044P 20011107 (60)
US 2001-331310P 20011114 (60)
US 2001-341237P 20011220 (60)
US 2002-369860P 20020405 (60)
DT Utility
FS APPLICATION
LREP HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
CLMN Number of Claims: 77
ECL Exemplary Claim: 1
DRWN 3 Drawing Page(s)
LN.CNT 11875
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to antibodies and related molecules that immunospecifically bind to TRAIL receptor, TR4. Such antibodies have uses, for example, in the prevention and treatment of cancers and other proliferative disorders. The invention also relates to nucleic acid molecules encoding anti-TR4 antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other hyperproliferative disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that immunospecifically bind to TRAIL receptor TR4.
IT 284461-73-0, BAY 43-9006
(anti-human TRAIL receptor TR4 antibodies and scFvs for diagnosis and treatment of cancer or hyperproliferative disease)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L15 ANSWER 320 OF 335 USPATFULL on STN
AN 2003:258389 USPATFULL
TI omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Piittsburgh, PA (non-U.S. corporation)
PI US 20030181442 A1 20030925
AI US 2001-993647 A1 20011127 (9)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3729
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P,
N-(4-Chloro-3-trifluoromethylphenyl)-N'-[4-[(2-carbamoyl-4-pyridyl)oxy]phenyl]urea 284461-82-1P 284461-88-7P
284462-04-0P 284462-05-1P 284462-17-5P
284462-18-6P 284462-21-1P 604813-04-9P,
N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[3-[5-[[2-(dimethylamino)ethyl]carbamoyl]pyridyl]oxy]phenyl]urea
(preparation of omega-carboxyaryl substituted di-Ph ureas as raf kinase inhibitors and anticancer agents)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 604813-04-9 USPATFULL
CN 3-Pyridinecarboxamide, 6-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



L15 ANSWER 321 OF 335 USPATFULL on STN
AN 2003:207917 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (non-U.S. corporation)
PI US 20030144278 A1 20030731
AI US 2002-283248 A1 20021030 (10) ABN
RLI Continuation of Ser. No. US 2002-42203, filed on 11 Jan 2002, PENDING
PRAI US 2001-367380P 20010112 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3733
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284461-82-1P 284461-88-7P 284461-98-9P 284462-04-0P 284462-05-1P 284462-17-5P 284462-18-6P, N-[4-Bromo-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea 284462-21-1P 474642-55-2P
(preparation of diphenylureas as RAF kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 474642-55-2 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



L15 ANSWER 322 OF 335 USPATFULL on STN
AN 2003:201617 USPATFULL
TI Method and/or process for preparing omega-carboxyaryl substituted diphenyl ureas as raf kinas inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., North Haven, CT, UNITED STATES
PI US 20030139605 A1 20030724
US 7528255 B2 20090505 compound claims
AI US 2002-71248 A1 20020211 (10)
RLI Continuation of Ser. No. US 2001-948915, filed on 10 Sep 2001, PENDING
Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 25
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3287
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy of the formula

A--D--B wherein

D is --NH--C(O)--NH--

A is a substituted moiety of the formula: --L--(M--L.sup.1).sub.q, and

B is a substituted or unsubstituted up to tricyclic aryl or heteroaryl moiety with a t least one 6-member cyclic structure bound directly to D containing 0-4 members of the group consisting of nitrogen oxygen and sulfur.

L is a 5-6 membered cyclic structure bound directly to D,

L.sup.1 comprises a substituted cyclic moiety having at least 5 members

M is a bridging group having at least one atom and q is an integer of from 1-3.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


CF3
Cl
O
N
NH
C
NH
MeNH
C
O
O

L15 ANSWER 323 OF 335 USPATFULL on STN
AN 2003:181526 USPATFULL
TI RAF-MEK-ERK pathway inhibitors to treat cancer
IN Lyons, John F., Moraga, CA, UNITED STATES
Bollag, Gideon, Hercules, CA, UNITED STATES
PI US 20030125359 A1 20030703
US 7307071 B2 20071211
AI US 2002-308721 A1 20021203 (10)
PRAI US 2001-336886P 20011204 (60)
DT Utility
FS APPLICATION
LREP Gregory Giotta, Ph.D., Vice President and Chief Legal Counsel, ONYX Pharmaceuticals, Inc., 3031 Research Drive, Richmond, CA, 94806
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 5 Drawing Page(s)
LN.CNT 373
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Materials and methods for treating certain cancers are described, preferably cancers that result from the up-regulation of the RAF-MEK-ERK pathway, and more preferably chronic myelogenous leukemia, and which cancer is preferably resistant to the inhibition of the Bcr-Abl tyrosine kinase, imatinib.
IT 284461-73-0, BAY 43-9006
(BAY 43-9006; RAF-MEK-ERK pathway inhibitors to treat cancer)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 324 OF 335 USPATFULL on STN
AN 2003:153423 USPATFULL
TI Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Handen, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya, JAPAN
William, Scott J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Naero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PI US 20030105091 A1 20030605
AI US 2002-86417 A1 20020304 (10) abn
RLI Continuation of Ser. No. US 1999-425229, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257265, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115878P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 4076
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating p38 mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-73-0P 284461-74-1P 284461-82-1P
284461-88-7P 284461-98-9P 284462-04-0P
284462-05-1P 284462-17-5P 284462-18-6P
284462-21-1P
(preparation of ω-carboxy aryl substituted di-Ph ureas as p38 kinase inhibitors)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



L15 ANSWER 325 OF 335 USPATFULL on STN
AN 2002:295343 USPATFULL
TI Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
IN Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Khire, Uday, Hamden, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Robert, Sibley N., North Haven, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Renick, Joel, Milford, CT, UNITED STATES
Gunn, David E., Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
PA BAYER CORPORATION (U.S. corporation)
PI US 20020165394 A1 20021107
AI US 2001-777920 A1 20010207 (9) no ODP
RLI Continuation-in-part of Ser. No. US 2001-758548, filed on 12 Jan 2001, PENDING Continuation-in-part of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 33
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3722
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions in such therapy.
IT 284461-73-0P 284461-74-1P 284461-82-1P
284461-88-7P 284461-98-9P 284462-04-0P
284462-05-1P 284462-17-5P 284462-18-6P
284462-21-1P
(drug candidate; preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




RN 284461-74-1 USPATFULL

CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 474642-55-2
(preparation of quinolyl, isoquinolyl or pyridyl-ureas as inhibitors of raf kinase)
RN 474642-55-2 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



L15 ANSWER 326 OF 335 USPATFULL on STN
AN 2002:262209 USPATFULL
TI Death domain containing receptor-4 antibodies
IN Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Pan, James G., Ypsilanti, MI, United States
Gentz, Reiner L., Silver Spring, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6461823 B1 20021008
AI US 1999-448868 19991124 (9)
RLI Division of Ser. No. US 1998-13895, filed on 27 Jan 1998, now patented, Pat. No. US 6342363
PRAI US 1997-37829P 19970205 (60)
US 1997-35722P 19970128 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine; Assistant Examiner: Kaufman, Claire M.
LREP Sterne, Kessler, Goldstein & Fox, P.L.L.C.
CLMN Number of Claims: 146
ECL Exemplary Claim: 135
DRWN 13 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 3073
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.
IT 284461-73-0, BAY 43-9006
(combination chemotherapy with; death domain containing receptor DR4 and methods for inducing apoptosis and treating cancer with DR4 agonist antibodies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 327 OF 335 USPATFULL on STN
AN 2002:251820 USPATFULL
TI Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Orange, CT, UNITED STATES
Khire, Uday, Hamden, CT, UNITED STATES
Lowinger, Timothy B., Nishinomiya City, CANADA
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Renick, Joel, San Diego, CA, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA (non-U.S. corporation)
PI US 20020137774 A1 20020926
AI US 2001-907970 A1 20010719 (9) abn
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3732
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 328 OF 335 USPATFULL on STN
AN 2002:185638 USPATFULL
TI Death domain containing receptor 5
IN Ni, Jian, Rockville, MD, UNITED STATES
Gentz, Reiner L., Silver Spring, MD, UNITED STATES
Yu, Guo-Liang, Darnestown, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA Human Genome Sciences, Inc. (U.S. corporation)
PI US 20020098550 A1 20020725
AI US 2001-5842 A1 20011207 (10)
RLI Division of Ser. No. US 1998-42583, filed on 17 Mar 1998, PENDING
PRAI US 1997-40846P 19970317 (60)
US 1997-54021P 19970729 (60)
DT Utility
FS APPLICATION
LREP STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 2876
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
IT 284461-73-0, BAY 43-9006
(combination chemotherapy with; DR5-binding agonist antibodies for induction of apoptosis in DR5 expressing cells and for treatment of cancer and hepatitis C virus infections)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 329 OF 335 USPATFULL on STN
AN 2002:78859 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Uday, Khire, Hamden, CT, UNITED STATES
Dumas, Jacques, Orange, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Lowinger, Timothy B., Nishinomiya City, JAPAN
Scott, William J., Guilford, CT, UNITED STATES
Smith, Roger A., Madison, CT, UNITED STATES
Wood, Jill E., Hamden, CT, UNITED STATES
Monahan, Mary-Katherine, Hamden, CT, UNITED STATES
Natero, Reina, Hamden, CT, UNITED STATES
Joel, Renick, Milford, CT, UNITED STATES
Sibley, Robert N., North Haven, CT, UNITED STATES
PA BAYER CORPORATION, Pittsburgh, PA, 15205 (U.S. corporation)
PI US 20020042517 A1 20020411
AI US 2001-948915 A1 20010910 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, ABANDONED
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60) abn
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3675
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-

(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 330 OF 335 USPATFULL on STN
AN 2002:19187 USPATFULL
TI Death domain containing receptor 4 nucleic acids and methods
IN Ni, Jian, Rockville, MD, United States
Rosen, Craig A., Laytonsville, MD, United States
Pan, James G., Ypsilanti, MI, United States
Gentz, Reiner L., Silver Spring, MD, United States
Dixit, Vishva M., Los Altos Hills, CA, United States
PA Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)
PI US 6342363 B1 20020129
AI US 1998-13895 19980127 (9)
PRAI US 1997-35722P 19970128 (60)
US 1997-37829P 19970205 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Spector, Lorraine; Assistant Examiner: Kaufman, Claire M.
LREP Sterne, Kessler, Goldstein & Fox PLLC
CLMN Number of Claims: 303
ECL Exemplary Claim: 286
DRWN 13 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 3345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.
IT 284461-73-0, BAY 43-9006
(combination chemotherapy with; death domain containing receptor DR4 and methods for inducing apoptosis and treating cancer with DR4 agonist antibodies)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)




COMMAND INTERRUPTED

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=> d l15 331-335 bib,ab,hitstr

L15 ANSWER 331 OF 335 USPATFULL on STN
AN 2001:188813 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy P., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Handen, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010034447 A1 20011025
AI US 2001-773604 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60) ABN
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3666
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 332 OF 335 USPATFULL on STN
AN 2001:171152 USPATFULL
TI Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jaques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., Noth Haven, CT, United States
PI US 20010027202 A1 20011004 abn
AI US 2001-773658 A1 20010202 (9)
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Arlington Courthouse Plaza I, Suite 1400, 2200 Clarendon Boulevard, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3656
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 333 OF 335 USPATFULL on STN
AN 2001:139616 USPATFULL
TI Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wupperal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nashnomya City, Japan
Scott, William J., Gulford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Rena, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010016659 A1 20010823
AI US 2001-773672 A1 20010202 (9) abn
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3652
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 334 OF 335 USPATFULL on STN
AN 2001:123628 USPATFULL
TI omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010011136 A1 20010802
AI US 2001-773675 A1 20010202 (9) abn
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, 2200 Clarendon Blvd., Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3646
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P 284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)




RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



L15 ANSWER 335 OF 335 USPATFULL on STN
AN 2001:123627 USPATFULL
TI Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors
IN Riedl, Bernd, Wuppertal, Germany, Federal Republic of
Dumas, Jacques, Orange, CT, United States
Khire, Uday, Hamden, CT, United States
Lowinger, Timothy B., Nishinomiya City, Japan
Scott, William J., Guilford, CT, United States
Smith, Roger A., Madison, CT, United States
Wood, Jill E., Hamden, CT, United States
Monahan, Mary-Katherine, Hamden, CT, United States
Natero, Reina, Hamden, CT, United States
Renick, Joel, Milford, CT, United States
Sibley, Robert N., North Haven, CT, United States
PI US 20010011135 A1 20010802
AI US 2001-773659 A1 20010202 (9) abn
RLI Continuation of Ser. No. US 1999-425228, filed on 22 Oct 1999, PENDING
Continuation-in-part of Ser. No. US 1999-257266, filed on 25 Feb 1999, ABANDONED
PRAI US 1999-115877P 19990113 (60)
DT Utility
FS APPLICATION
LREP MILLEN, WHITE, ZELANO & BRANIGAN, P.C., Suite 1400, Arlington Courthouse Plaza 1, Arlington, VA, 22201
CLMN Number of Claims: 67
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3686
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.
IT 284461-74-1P, N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-carbamoyl-4-pyridyloxy)phenyl]urea 284462-05-1P
284462-17-5P 284462-18-6P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-74-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]- (CA INDEX NAME)



RN 284462-05-1 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-[2-(dimethylamino)ethyl]- (CA INDEX NAME)



RN 284462-17-5 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(2-hydroxyethyl)- (CA INDEX NAME)



RN 284462-18-6 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



IT 284461-82-1P 284461-88-7P 284461-98-9P
284462-04-0P 284462-21-1P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-82-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



RN 284461-88-7 USPATFULL
CN 2-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284461-98-9 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-(1-methylethyl)- (CA INDEX NAME)



RN 284462-04-0 USPATFULL
CN 3-Pyridinecarboxamide, 5-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



RN 284462-21-1 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-bromo-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-ethyl- (CA INDEX NAME)



IT 284461-73-0P
(preparation of ω-carboxy(hetero)aryl substituted di-Ph urea raf kinase inhibitors by reacting arylisocyanates with arylamines)
RN 284461-73-0 USPATFULL
CN 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)



```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   249.96     539.11

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -9.57

STN INTERNATIONAL LOGOFF AT 08:03:40 ON 18 JAN 2011
```